Impact of Procalcitonin-guided Algorithm on Early Discontinuation of Antibiotic Therapy
- Disease/Condition
- Bacterial Infections
- Drug/Device/Intervention
- Measurement of the PCT plasma levels
- Study type
- Interventional
- Intervention type
- procedure
- Primary sponsor
- University Hospital, Toulouse
- Location
- Amiens,Clermont-Ferrand,Nantes,Toulouse, France
- Phase
- N/A
- Start date
- Jan 01, 2023
- End date
- Mar 01, 2024
- Enrollment
- 296 participants
Total duration of antibiotic therapy (in days) for a suspected or proven bacterial infection, including the first episode and recurrences occurring within 28 days following the day of randomization
In this randomized controlled open-label trial, conducted in 7 French Pediatric and Neonatal
 Intensive Care Units (ICUs), investigator team hypothesize that the use of a procalcitonin
 (PCT)-guided algorithm to discontinue antibiotic treatment will decrease antibiotic duration
 in critically ill children treated for a suspected or proven bacterial infection. Two hundred
 and ninety-six eligible patients will be randomly assigned in two groups: either PCT-guided
 or standard-of-care antibiotic discontinuation, and monitored over 28 days, until the end of
 their hospitalization, or up to the end of antibiotic treatment for bacterial infection
 recurrence occurring up to 28 days after the day of randomization.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05350813
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05350813 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Toulouse and is currently Not yet recruiting. The study focuses on Bacterial Infections. Target enrollment is 296 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.